Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Goserelin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR known ✓ | P30968 | 2/20 | 0.73 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.72 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | APLNR | P35414 | 4/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Goserelin SCHEMBL4735617 | 0.99 | ABCC2 (0.74) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Goserelin SCHEMBL7202372 | 0.99 | ABCC2 (0.74) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Buserelin SCHEMBL3467577 | 0.98 | GNRHR (0.75) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Buserelin SCHEMBL2544038 | 0.98 | ABCC2 (0.76) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Goserelin SCHEMBL8836302 | 0.96 | GNRHR (0.66) | GNRHRABCC2PTGS1APLNR | |
| Buserelin SCHEMBL15214196 | 0.95 | GNRHR (0.80) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Buserelin SCHEMBL29598917 | 0.95 | GNRHR (0.80) | GNRHRABCC2PTGS1APLNRCXCR4 | |
| Buserelin SCHEMBL14193133 | 0.95 | GNRHR (0.68) | GNRHRABCC2PTGS1APLNR | |
| Buserelin SCHEMBL16766450 | 0.95 | GNRHR (0.68) | GNRHRABCC2PTGS1APLNR | |
| Buserelin SCHEMBL6676660 | 0.95 | GNRHR (0.68) | GNRHRABCC2PTGS1APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576921-B2 | Pharmaceutical compositions and methods | POP TEST ONCOLOGY LLC (US) | 2023-02-14 | — | — | US | claimed |
| EP-3912626-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | The University of Chicago (US) | 2021-11-24 | — | — | EP | claimed |
| EP-3111950-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | The University of Chicago (US) | 2017-01-04 | — | — | EP | claimed |
| US-9289436-B2 | Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists | THE UNIVERSITY OF CHICAGO (US) | 2016-03-22 | — | — | US | claimed |
| US-20150010503-A1 | Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer | THE UNIVERSITY OF CHICAGO (US) | 2015-01-08 | — | — | US | claimed |
| EP-2817019-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | The University of Chicago (US) | 2014-12-31 | — | — | EP | claimed |
| WO-2013126581-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | THE UNIVERSITY OF CHICAGO (US) | 2013-08-29 | — | — | WO | claimed |
| US-20230375551-A1 | METHODS FOR CONFIRMING DETECTION AND EVALUATING THE PROGRESSION OF A PROSTATE CANCER AND RELATED THERAPIES | Metirra Pty Ltd (AU) | 2023-11-23 | — | — | US | disclosed |
| WO-2023192291-A2 | INDOLIUM COMPOUNDS FOR TREATING CANCER | EMORY UNIVERSITY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230218634-A1 | METHODS OF TREATING CASTRATION-RESISTANT PROSTATE CANCER WITH GLUCOCORTICOID RECEPTOR ANTAGONISTS AND ANTI-ANDROGEN RECEPTOR THERAPY AND ANTI-ANDROGEN RECEPTOR THERAPY | UNIVERSITY OF CHICAGO (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230099637-A1 | Palladium Hyaluronic Acid Particles and Methods of Managing Cancer or Angiogenic Conditions | UNIV EMORY (US) | 2023-03-30 | — | — | US | disclosed |
| US-11564932-B2 | Methods of treating castration-resistant prostate cancer with glucocorticoid receptor antagonists and anti-androgen receptor therapy | THE UNIVERSITY OF CHICAGO (US) | 2023-01-31 | — | — | US | disclosed |
| EP-3111950-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | The University of Chicago (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160151388-A1 | Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer | THE UNIVERSITY OF CHICAGO | 2016-06-02 | — | — | US | disclosed |
| US-9289436-B2 | Method of treatment of prostate cancer with androgen receptor and glucocorticoid receptor antagonists | THE UNIVERSITY OF CHICAGO (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150010503-A1 | Methods and Compositions Related to Glucocorticoid Receptor Antagonism and Prostate Cancer | THE UNIVERSITY OF CHICAGO (US) | 2015-01-08 | — | — | US | disclosed |
| EP-2817019-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | The University of Chicago (US) | 2014-12-31 | — | — | EP | disclosed |
| WO-2013126581-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | THE UNIVERSITY OF CHICAGO (US) | 2013-08-29 | — | — | WO | disclosed |
| US-20070161546-A1 | Methods and compositions for treatment of cancer | CAVIT SCIENCES, INC. | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | GNRHR 3450/4885ABCC2 3446/4885PTGS1 2977/4885 |
| US-11576921-B2 | Pharmaceutical compositions and methods | NR3C2, NR3C1, MC2R | GNRHR 65/4885ABCC2 3361/4885PTGS1 136/4885 |
| US-20070161546-A1 | Methods and compositions for treatment of cancer | TP53, TMSB10, TERT | GNRHR 4764/4885ABCC2 1404/4885PTGS1 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.